Kyowa Kirin Co Ltd (TSE: 4151), a Japan-based Global Specialty Pharmaceutical Company, announced on Tuesday that it has enrolled its first subject in a phase two clinical trial, multi-centre, randomised, double-masked, parallel group study of tivozanib eye drops (KHK4951).
The study is to assess the efficacy and safety of KHK4951 in patients with diabetic macular edema (DME). KHK4951 is a novel nano-crystalised tivozanib eye drop designed for delivery to the posterior ocular tissues and is being developed as a potential treatment option for neovascular (wet) age-related macular degeneration (nAMD) and DME.
Presently, an oral formulation of tivozanib is marketed as FOTIVDA in the US by AVEO Oncology, an LG Chem Company, and in Europe by EUSA Pharma (UK) Ltd for another indication.
The Phase two study will be enrolling 150 subjects with DME across the US, Japan, Australia and South Korea. The primary outcome measure is reduction of 15 or more letters from baseline in BCVA (Best Corrected Visual Acuity) as measured by the ETDRS visual acuity chart.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration